These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28637022)

  • 1. CDKN2A methylation in esophageal cancer: a meta-analysis.
    Zhou C; Li J; Li Q
    Oncotarget; 2017 Jul; 8(30):50071-50083. PubMed ID: 28637022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
    Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
    Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
    Abou-Zeid AA; Azzam AZ; Kamel NA
    Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis.
    Li J; Zhou C; Zhou H; Bao T; Gao T; Jiang X; Ye M
    Ther Clin Risk Manag; 2016; 12():1249-60. PubMed ID: 27574435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of hypermethylation of p16 gene in esophageal cancer.
    Xu R; Wang F; Wu L; Wang J; Lu C
    Cancer Biomark; 2013; 13(4):215-26. PubMed ID: 24240582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of risk factors obesity and occupational airborne exposures with CDKN2A/p16 aberrant DNA methylation in esophageal cancer patients.
    Mohammad Ganji S; Miotto E; Callegari E; Sayehmiri K; Fereidooni F; Yazdanbod M; Rastgar-Jazii F; Negrini M
    Dis Esophagus; 2010 Sep; 23(7):597-602. PubMed ID: 20459442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
    Zhou Y; Wang XB; Qiu XP; Shuai Zhang ; Wang C; Zheng F
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):529-541. PubMed ID: 30143452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.
    Tang B; Li Y; Qi G; Yuan S; Wang Z; Yu S; Li B; He S
    Sci Rep; 2015 Sep; 5():13563. PubMed ID: 26338139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex.
    Alves MK; Faria MH; Neves Filho EH; Ferrasi AC; Pardini MI; de Moraes Filho MO; Rabenhorst SH
    Int J Surg; 2013; 11(7):549-53. PubMed ID: 23721661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma.
    Ito S; Ohga T; Saeki H; Watanabe M; Kakeji Y; Morita M; Yamada T; Maehara Y
    Anticancer Res; 2007; 27(5A):3345-53. PubMed ID: 17970080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma.
    Su L; Wang H; Miao J; Liang Y
    Sci Rep; 2015 Aug; 5():13238. PubMed ID: 26283007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer.
    Lamy A; Sesboüé R; Bourguignon J; Dautréaux B; Métayer J; Frébourg T; Thiberville L
    Int J Cancer; 2002 Jul; 100(2):189-93. PubMed ID: 12115568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
    Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
    PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of
    Li J; Ye D; Wang L; Peng Y; Li Q; Deng H; Zhou C
    Onco Targets Ther; 2018; 11():651-663. PubMed ID: 29440913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between P16
    Poosari A; Nutravong T; Namwat W; Wasenang W; Sa-Ngiamwibool P; Ungareewittaya P
    Sci Rep; 2022 Jun; 12(1):10337. PubMed ID: 35725923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma.
    Hibi K; Taguchi M; Nakayama H; Takase T; Kasai Y; Ito K; Akiyama S; Nakao A
    Clin Cancer Res; 2001 Oct; 7(10):3135-8. PubMed ID: 11595706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methylation of p16 and hMLH1 genes in esophageal squamous cell carcinoma and reflux esophagitis].
    Wang F; Xie XJ; Piao YS; Liu B; Wang LD
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):537-41. PubMed ID: 22169643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
    Cao Z; Wei L; Zhu W; Yao X
    Medicine (Baltimore); 2018 Mar; 97(12):e0182. PubMed ID: 29561434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
    Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
    Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.